We are live on ! Find out more
TXMD icon

TherapeuticsMD

49 hedge funds and large institutions have $7.97M invested in TherapeuticsMD in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,998% more capital inflows, than outflows

Capital inflows: $2.23M | Capital outflows: $71.8K

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

11% more funds holding

Funds holding: 44 → 49 (+5)

4.84% more ownership

Funds ownership: 29.25% → 34.09% (+4.8%)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Holders
49
Holders Change
+5
Holders Change %
+11.36%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
8
Reduced
8
Closed
3
Calls
$105​K
Puts
–
Net Calls
+$105​K
Net Calls Change
-⁠$8​K

TXMD Hedge Fund Activity: Q1 2026 in Review

49 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2026, worth a combined $7.97M — up 44% from $5.52M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TXMD positions and 3 closed out — a net gain of 7 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $945K. The largest seller was Susquehanna International Group, cutting an estimated $31.4K.

  • 49 institutional investors held TherapeuticsMD (TXMD) as of Q1 2026, up from 44 in Q4 2025.
  • Funds reported $7.97M of TherapeuticsMD stock for Q1 2026, up 44% quarter-over-quarter.
  • 10 funds opened new TherapeuticsMD positions in Q1 2026 and 3 closed out, a net change of +7 holders.
  • The largest TherapeuticsMD buyer in Q1 2026 was Squadron Capital Management, an estimated $945K added.
  • The largest TherapeuticsMD seller in Q1 2026 was Susquehanna International Group, an estimated $31.4K sold.

Based on aggregated 13F filings for Q1 2026.